1. Home
  2. CEG vs REGN Comparison

CEG vs REGN Comparison

Compare CEG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CEG
  • REGN
  • Stock Information
  • Founded
  • CEG 1999
  • REGN 1988
  • Country
  • CEG United States
  • REGN United States
  • Employees
  • CEG N/A
  • REGN N/A
  • Industry
  • CEG Electric Utilities: Central
  • REGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CEG Utilities
  • REGN Health Care
  • Exchange
  • CEG Nasdaq
  • REGN Nasdaq
  • Market Cap
  • CEG 65.5B
  • REGN 63.4B
  • IPO Year
  • CEG N/A
  • REGN 1991
  • Fundamental
  • Price
  • CEG $271.37
  • REGN $527.78
  • Analyst Decision
  • CEG Buy
  • REGN Buy
  • Analyst Count
  • CEG 13
  • REGN 23
  • Target Price
  • CEG $288.00
  • REGN $907.39
  • AVG Volume (30 Days)
  • CEG 3.1M
  • REGN 1.3M
  • Earning Date
  • CEG 05-06-2025
  • REGN 04-29-2025
  • Dividend Yield
  • CEG 0.57%
  • REGN 0.33%
  • EPS Growth
  • CEG 26.52
  • REGN 16.49
  • EPS
  • CEG 9.49
  • REGN 39.43
  • Revenue
  • CEG $24,195,000,000.00
  • REGN $14,085,700,000.00
  • Revenue This Year
  • CEG $1.23
  • REGN $2.38
  • Revenue Next Year
  • CEG $3.21
  • REGN $7.65
  • P/E Ratio
  • CEG $28.59
  • REGN $13.39
  • Revenue Growth
  • CEG 2.90
  • REGN 7.52
  • 52 Week Low
  • CEG $155.60
  • REGN $525.99
  • 52 Week High
  • CEG $352.00
  • REGN $1,211.20
  • Technical
  • Relative Strength Index (RSI)
  • CEG 69.92
  • REGN 35.08
  • Support Level
  • CEG $241.46
  • REGN $520.50
  • Resistance Level
  • CEG $279.89
  • REGN $615.61
  • Average True Range (ATR)
  • CEG 10.01
  • REGN 22.65
  • MACD
  • CEG 6.74
  • REGN -2.54
  • Stochastic Oscillator
  • CEG 89.86
  • REGN 7.65

About CEG Constellation Energy Corporation

Constellation Energy Corp producer of carbon-free energy and a supplier of energy products and services. The company offers generating capacity that includes nuclear, wind, solar, natural gas, and hydroelectric assets. It sells electricity, natural gas, and other energy-related products and sustainable solutions to various types of customers, including distribution utilities, municipalities, cooperatives, and commercial, industrial, public sector, and residential customers in markets across multiple geographic regions. Its operating segments and reporting units are Mid-Atlantic, Midwest, New York, ERCOT, and Other Power Regions.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: